Arcutis Submits Roflumilast Cream 0.05% (Zoryve) sNDA to the FDA for Mild to Moderate AD in Children Aged 2 to 5
Arcutis Biotherapeutics, Inc. has submitted of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for roflumilast) cream 0.05% (Zoryve) for mild to moderate AD in children aged 2 to 5. “When choosing a therapy for very young children living with AD, healthcare providers and caregivers have to account for […]